{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:21:54Z","timestamp":1792030914394,"version":"4.4.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T00:00:00Z","timestamp":1488499200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s00296-017-3686-5","type":"journal-article","created":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T17:25:30Z","timestamp":1488561930000},"page":"1249-1255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence"],"prefix":"10.1007","volume":"37","author":[{"given":"Savino","family":"Sciascia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Radin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinoos","family":"Yazdany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Tektonidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Cecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Roccatello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Dall\u2019Era","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,3]]},"reference":[{"key":"3686_CR1","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.autrev.2016.03.002","volume":"15","author":"H Wu","year":"2016","unstructured":"Wu H, Zhao M, Tan L, Lu Q (2016) The key culprit in the pathogenesis of systemic lupus erythematosus: aberrant DNA methylation. Autoimmun Rev 15:684\u2013689. doi:\n10.1016\/j.autrev.2016.03.002","journal-title":"Autoimmun Rev"},{"key":"3686_CR2","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/ni0901-764","volume":"2","author":"PE Lipsky","year":"2001","unstructured":"Lipsky PE (2001) Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2:764\u2013766. doi:\n10.1038\/ni0901-764","journal-title":"Nat Immunol"},{"key":"3686_CR3","doi-asserted-by":"publisher","first-page":"419029","DOI":"10.1155\/2014\/419029","volume":"2014","author":"A Mak","year":"2014","unstructured":"Mak A, Kow NY (2014) The pathology of T cells in systemic lupus erythematosus. J Immunol Res 2014:419029. doi:\n10.1155\/2014\/419029","journal-title":"J Immunol Res"},{"key":"3686_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.07.033","author":"M Schneider","year":"2016","unstructured":"Schneider M (2016) Pitfalls in lupus. Autoimmun Rev. doi:\n10.1016\/j.autrev.2016.07.033","journal-title":"Autoimmun Rev"},{"key":"3686_CR5","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1056\/NEJMoa021933","volume":"349","author":"MR Arbuckle","year":"2003","unstructured":"Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA et al (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349:1526\u20131533. doi:\n10.1056\/NEJMoa021933","journal-title":"N Engl J Med"},{"key":"3686_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nrrheum.2015.151","volume":"12","author":"DS Pisetsky","year":"2015","unstructured":"Pisetsky DS (2015) Anti-DNA antibodies\u2014quintessential biomarkers of SLE. Nat Rev Rheumatol 12:102\u2013110. doi:\n10.1038\/nrrheum.2015.151","journal-title":"Nat Rev Rheumatol"},{"key":"3686_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.autrev.2015.08.007","volume":"15","author":"M Frieri","year":"2016","unstructured":"Frieri M, Stampfl H (2016) Systemic lupus erythematosus and atherosclerosis: review of the literature. Autoimmun Rev 15:16\u201321. doi:\n10.1016\/j.autrev.2015.08.007","journal-title":"Autoimmun Rev"},{"key":"3686_CR8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.coi.2012.08.004","volume":"24","author":"KB Elkon","year":"2012","unstructured":"Elkon KB, Santer DM (2012) Complement, interferon and lupus. Curr Opin Immunol 24:665\u2013670. doi:\n10.1016\/j.coi.2012.08.004","journal-title":"Curr Opin Immunol"},{"key":"3686_CR9","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1006\/clim.1999.4813","volume":"95","author":"MC Carroll","year":"2000","unstructured":"Carroll MC (2000) A protective role for innate immunity in autoimmune disease. Clin Immunol 95:S30\u2013S38. doi:\n10.1006\/clim.1999.4813","journal-title":"Clin Immunol"},{"key":"3686_CR10","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/90686","volume":"2","author":"Z Kaya","year":"2001","unstructured":"Kaya Z, Afanasyeva M, Wang Y, Dohmen KM, Schlichting J, Tretter T et al (2001) Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nat Immunol 2:739\u2013745. doi:\n10.1038\/90686","journal-title":"Nat Immunol"},{"key":"3686_CR11","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.4049\/jimmunol.169.4.2126","volume":"169","author":"SD Fleming","year":"2002","unstructured":"Fleming SD, Shea-Donohue T, Guthridge JM, Kulik L, Waldschmidt TJ, Gipson MG et al (2002) Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. J Immunol 169:2126\u20132133","journal-title":"J Immunol"},{"key":"3686_CR12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0065-2776(08)60908-6","volume":"74","author":"MC Carroll","year":"2000","unstructured":"Carroll MC (2000) The role of complement in B cell activation and tolerance. Adv Immunol 74:61\u201388","journal-title":"Adv Immunol"},{"key":"3686_CR13","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.clim.2013.02.014","volume":"148","author":"ML Barilla-LaBarca","year":"2013","unstructured":"Barilla-LaBarca ML, Toder K, Furie R (2013) Targeting the complement system in systemic lupus erythematosus and other diseases. Clin Immunol 148:313\u2013321. doi:\n10.1016\/j.clim.2013.02.014","journal-title":"Clin Immunol"},{"key":"3686_CR14","doi-asserted-by":"crossref","first-page":"8563","DOI":"10.1073\/pnas.93.16.8563","volume":"93","author":"Y Wang","year":"1996","unstructured":"Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Matis LA (1996) Amelioration of lupus-like autoimmune disease in NZB\/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA 93:8563\u20138568","journal-title":"Proc Natl Acad Sci USA"},{"key":"3686_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1546-0096-10-21","volume":"10","author":"A Belot","year":"2012","unstructured":"Belot A, Cimaz R (2012) Monogenic forms of systemic lupus erythematosus: new insights into SLE pathogenesis. Pediatr Rheumatol Online J 10:21. doi:\n10.1186\/1546-0096-10-21","journal-title":"Pediatr Rheumatol Online J"},{"key":"3686_CR16","doi-asserted-by":"publisher","first-page":"3966","DOI":"10.1002\/art.21484","volume":"52","author":"YH Lee","year":"2005","unstructured":"Lee YH, Witte T, Momot T, Schmidt RE, Kaufman KM, Harley JB et al (2005) The mannose-binding lectin gene polymorphisms and systemic lupus erythematosus: two case-control studies and a meta-analysis. Arthritis Rheum 52:3966\u20133974. doi:\n10.1002\/art.21484","journal-title":"Arthritis Rheum"},{"key":"3686_CR17","doi-asserted-by":"publisher","first-page":"R206","DOI":"10.1186\/ar3539","volume":"13","author":"A J\u00f6nsen","year":"2011","unstructured":"J\u00f6nsen A, Nilsson SC, Ahlqvist E, Svenungsson E, Gunnarsson I, Eriksson KG et al (2011) Mutations in genes encoding complement inhibitors CD46 and CFH affect the age at nephritis onset in patients with systemic lupus erythematosus. Arthritis Res Ther 13:R206. doi:\n10.1186\/ar3539","journal-title":"Arthritis Res Ther"},{"key":"3686_CR18","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1056\/NEJMoa031688","volume":"350","author":"P Hillmen","year":"2004","unstructured":"Hillmen P, Hall C, Marsh JCW, Elebute M, Bombara MP, Petro BE et al (2004) Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 350:552\u2013559. doi:\n10.1056\/NEJMoa031688","journal-title":"N Engl J Med"},{"key":"3686_CR19","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C et al (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169\u20132181. doi:\n10.1056\/NEJMoa1208981","journal-title":"N Engl J Med"},{"key":"3686_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.07.020","author":"K Oku","year":"2016","unstructured":"Oku K, Nakamura H, Kono M, Ohmura K, Kato M, Bohgaki T et al (2016) Complement and thrombosis in the antiphospholipid syndrome. Autoimmun Rev. doi:\n10.1016\/j.autrev.2016.07.020","journal-title":"Autoimmun Rev"},{"key":"3686_CR21","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1515\/revneuro-2014-0021","volume":"25","author":"R Huda","year":"2014","unstructured":"Huda R, T\u00fcz\u00fcn E, Christadoss P (2014) Targeting complement system to treat myasthenia gravis. Rev Neurosci 25:575\u2013583. doi:\n10.1515\/revneuro-2014-0021","journal-title":"Rev Neurosci"},{"key":"3686_CR22","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.clim.2015.08.009","volume":"161","author":"ES Reis","year":"2015","unstructured":"Reis ES, Mastellos DC, Yancopoulou D, Risitano AM, Ricklin D, Lambris JD (2015) Applying complement therapeutics to rare diseases. Clin Immunol 161:225\u2013240. doi:\n10.1016\/j.clim.2015.08.009","journal-title":"Clin Immunol"},{"key":"3686_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11940-015-0387-9","volume":"18","author":"RA Kessler","year":"2016","unstructured":"Kessler RA, Mealy MA, Levy M (2016) Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic. Curr Treat Options Neurol 18:2. doi:\n10.1007\/s11940-015-0387-9","journal-title":"Curr Treat Options Neurol"},{"key":"3686_CR24","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/ccr3.399","volume":"3","author":"R Shapiro","year":"2015","unstructured":"Shapiro R, Chin-Yee I, Lam S (2015) Eculizumab as a bridge to immunosuppressive therapy in severe cold agglutinin disease of anti-Pr specificity. Clin Case Reports 3:942\u2013944. doi:\n10.1002\/ccr3.399","journal-title":"Clin Case Reports"},{"key":"3686_CR25","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3265\/Nefrologia.pre2014.Feb.12506","volume":"34","author":"J Manrique","year":"2014","unstructured":"Manrique J, Cravedi P (2014) Role of monoclonal antibodies in the treatment of immune-mediated glomerular diseases. Nefrol Publicaci\u00f3n Of La Soc Espa\u00f1ola Nefrol 34:388\u2013397. doi:\n10.3265\/Nefrologia.pre2014.Feb.12506","journal-title":"Nefrol Publicaci\u00f3n Of La Soc Espa\u00f1ola Nefrol"},{"key":"3686_CR26","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1056\/NEJMc0910965","volume":"362","author":"BE Lonze","year":"2010","unstructured":"Lonze BE, Singer AL, Montgomery RA (2010) Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med 362:1744\u20131745. doi:\n10.1056\/NEJMc0910965","journal-title":"N Engl J Med"},{"key":"3686_CR27","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMc1111953","volume":"366","author":"M Vivarelli","year":"2012","unstructured":"Vivarelli M, Pasini A, Emma F (2012) Eculizumab for the treatment of dense-deposit disease. N Engl J Med 366:1163\u20131165. doi:\n10.1056\/NEJMc1111953","journal-title":"N Engl J Med"},{"key":"3686_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14001","author":"S Kulkarni","year":"2016","unstructured":"Kulkarni S, Kirkiles-Smith NC, Deng YH, Formica RN, Moeckel G, Broecker V et al (2016) Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: a pilot, randomized-controlled trial. Am J Transplant. doi:\n10.1111\/ajt.14001","journal-title":"Am J Transplant"},{"key":"3686_CR29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00467-014-2944-y","volume":"30","author":"R Coppo","year":"2015","unstructured":"Coppo R, Peruzzi L, Amore A, Martino S, Vergano L, Lastauka I et al (2015) Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol 30:167\u2013172. doi:\n10.1007\/s00467-014-2944-y","journal-title":"Pediatr Nephrol"},{"key":"3686_CR30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1053\/j.ajkd.2014.07.031","volume":"65","author":"A El-Husseini","year":"2014","unstructured":"El-Husseini A, Hannan S, Awad A, Jennings S, Cornea V, Sawaya BP (2014) Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis 65:127\u2013130. doi:\n10.1053\/j.ajkd.2014.07.031","journal-title":"Am J Kidney Dis"},{"key":"3686_CR31","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1177\/2333794X15570150","volume":"2","author":"A Boneparth","year":"2015","unstructured":"Boneparth A, Moorthy LN, Weiss L, Rajasekhar H, Murphy S, Drachtman RA (2015) Complement inhibition in the treatment of SLE-associated thrombotic thrombocytopenic purpura. Glob Pediatr Heal 2:2015\u20132017. doi:\n10.1177\/2333794X15570150","journal-title":"Glob Pediatr Heal"},{"key":"3686_CR32","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1111\/j.1600-6143.2011.03696.x","volume":"11","author":"K Hadaya","year":"2011","unstructured":"Hadaya K, Ferrari-Lacraz S, Fumeaux D, Boehlen F, Toso C, Moll S et al (2011) Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant 11:2523\u20132527. doi:\n10.1111\/j.1600-6143.2011.03696.x","journal-title":"Am J Transplant"},{"key":"3686_CR33","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1097\/MD.0000000000000143","volume":"93","author":"A Kronbichler","year":"2014","unstructured":"Kronbichler A, Frank R, Kirschfink M, Szil\u00e1gyi \u00c1, Csuka D, Proh\u00e1szka Z et al (2014) Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine (Baltimore) 93:e143. doi:\n10.1097\/MD.0000000000000143","journal-title":"Medicine (Baltimore)"},{"key":"3686_CR34","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1093\/rheumatology\/kev307","volume":"54","author":"MC Pickering","year":"2015","unstructured":"Pickering MC, Ismajli M, Condon MB, McKenna N, Hall AE, Lightstone L et al (2015) Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatol (United Kingdom) 54:2286\u20132288. doi:\n10.1093\/rheumatology\/kev307","journal-title":"Rheumatol (United Kingdom)"},{"key":"3686_CR35","first-page":"1983","volume":"35","author":"MG Tektonidou","year":"2008","unstructured":"Tektonidou MG, Sotsiou F, Moutsopoulos HM (2008) Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary, and systemic lupus erythematosus-related APS. J Rheumatol 35:1983\u20131988","journal-title":"J Rheumatol"},{"key":"3686_CR36","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.20433","volume":"50","author":"MG Tektonidou","year":"2004","unstructured":"Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM (2004) Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum 50:2569\u20132579. doi:\n10.1002\/art.20433","journal-title":"Arthritis Rheum"},{"key":"3686_CR37","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1111\/ajt.12319","volume":"13","author":"G Canaud","year":"2013","unstructured":"Canaud G, Kamar N, Anglicheau D, Esposito L, Rabant M, No\u00ebl L-H et al (2013) Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant 13:2179\u20132185. doi:\n10.1111\/ajt.12319","journal-title":"Am J Transplant"},{"key":"3686_CR38","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nrneph.2014.38","volume":"10","author":"S Sciascia","year":"2014","unstructured":"Sciascia S, Cuadrado MJ, Khamashta M, Roccatello D (2014) Renal involvement in antiphospholipid syndrome. Nat Rev Nephrol 10:279\u2013289. doi:\n10.1038\/nrneph.2014.38","journal-title":"Nat Rev Nephrol"},{"key":"3686_CR39","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s12185-016-1946-x","volume":"103","author":"N Miyasaka","year":"2016","unstructured":"Miyasaka N, Miura O, Kawaguchi T, Arima N, Morishita E, Usuki K et al (2016) Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review. Int J Hematol 103:703\u2013712. doi:\n10.1007\/s12185-016-1946-x","journal-title":"Int J Hematol"},{"key":"3686_CR40","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s40620-015-0173-5","volume":"28","author":"Amorim E Sousa De","year":"2015","unstructured":"De Sousa Amorim E, Blasco M, Quintana L, Sole M, de Cordoba SR, Campistol JM (2015) Eculizumab in pregnancy-associated atypical hemolytic uremic syndrome: insights for optimizing management. J Nephrol 28:641\u2013645. doi:\n10.1007\/s40620-015-0173-5","journal-title":"J Nephrol"},{"key":"3686_CR41","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.semnephrol.2015.08.009","volume":"35","author":"S Sciascia","year":"2015","unstructured":"Sciascia S, Baldovino S, Schreiber K, Solfietti L, Roccatello D (2015) Antiphospholipid Syndrome and the Kidney. Semin Nephrol 35:478\u2013486. doi:\n10.1016\/j.semnephrol.2015.08.009","journal-title":"Semin Nephrol"},{"key":"3686_CR42","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jaut.2016.06.012","volume":"74","author":"G Moroni","year":"2016","unstructured":"Moroni G, Doria A, Giglio E et al (2016) Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study. J Autoimmun 74:194\u2013200. doi:\n10.1016\/j.jaut.2016.06.012","journal-title":"J Autoimmun"},{"key":"3686_CR43","first-page":"S35","volume":"50","author":"R Furie","year":"2004","unstructured":"Furie R, Matis L, Rollins S et al (2004) A single dose, placebocontrolled, double blind, phase I study of the humanized anti-C5 antibody h5G1.1 in patients with systemic lupus erythematosus. Arthritis Rheum 50:S35\u2013S747","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-017-3686-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-017-3686-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-017-3686-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T09:38:48Z","timestamp":1500975528000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-017-3686-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,3]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["3686"],"URL":"https:\/\/doi.org\/10.1007\/s00296-017-3686-5","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,3]]}}}